Manipulating signaling pathways in immune cells
Synthetic Biology and Optogenetics Core
This study is all about creating special tools to better understand how immune cells called macrophages work during lung inflammation, which can help us learn how to improve treatments for related conditions.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10895333 on NIH RePORTER |
What this research studies
This research focuses on developing advanced tools to manipulate and study specific signaling pathways in immune cells, particularly macrophages, which play a crucial role in lung inflammation and injury. By using engineered reagents, the project aims to gain insights into how these cells adapt and respond during inflammatory processes. The research involves creating customized molecular tools and applying them in mouse models to observe the effects on macrophage behavior and function. This approach allows for precise control over protein interactions and activities in living cells, enhancing our understanding of immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from lung conditions characterized by inflammation, such as asthma or chronic obstructive pulmonary disease (COPD).
Not a fit: Patients with non-inflammatory lung conditions or those not affected by macrophage-related processes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating lung inflammation and related diseases.
How similar studies have performed: Previous research has shown promising results using similar optogenetic and synthetic biology approaches to manipulate cellular signaling pathways, indicating potential for success in this area.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Karginov, Andrei V — University of Illinois at Chicago
- Study coordinator: Karginov, Andrei V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.